Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531624 | 0.84 | LTA4H (1.00) | LTA4H | |
| Hydrochloric Acid SCHEMBL1895851 | 0.83 | LTA4H (1.00) | LTA4H | |
| SCHEMBL7132938 | 0.81 | LTA4H (0.84) | LTA4HACHE | |
| SCHEMBL2108985 | 0.81 | LTA4H (0.69) | LTA4H | |
| SCHEMBL7141071 | 0.81 | LTA4H (0.92) | LTA4H | |
| Water SCHEMBL29674549 | 0.80 | LTA4H (0.82) | LTA4HACHE | |
| SCHEMBL24322921 | 0.79 | LTA4H (1.00) | LTA4HACHE | |
| SCHEMBL8112098 | 0.79 | LTA4H (0.65) | LTA4HACHE | |
| Hydrochloric Acid SCHEMBL8113562 | 0.78 | LTA4H (0.63) | LTA4HACHE | |
| SCHEMBL22686124 | 0.78 | LTA4H (0.82) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617597-B2 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2017-04-11 | — | — | US | disclosed |
| EP-2471954-B1 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2016-08-24 | — | — | EP | disclosed |
| EP-2155907-B1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENT OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2015-05-27 | — | — | EP | disclosed |
| US-20120208709-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | DECODE GENETICS EHF. (IS) | 2012-08-16 | — | — | US | disclosed |
| EP-2471954-A1 | Genetic susceptibility variants associated with cardiovascular disease | Decode Genetics EHF (IS) | 2012-07-04 | — | — | EP | disclosed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2010-05-13 | — | — | US | disclosed |
| US-20100068705-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | DECODE GENETICS EHF (IS) | 2010-03-18 | — | — | US | disclosed |
| EP-2155907-A2 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENT OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | Decode Genetics EHF (IS) | 2010-02-24 | — | — | EP | disclosed |
| EP-2115172-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | Decode Genetics EHF (IS) | 2009-11-11 | — | — | EP | disclosed |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | DECODE GENETICS EHF. (IS) | 2008-11-27 | — | — | US | disclosed |
| WO-2008132763-A2 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENT OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008102380-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | DECODE GENETICS EHF (IS) | 2008-08-28 | — | — | WO | disclosed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | disclosed |
| EP-1718284-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2006-11-08 | — | — | EP | disclosed |
| EP-1670445-A2 | METHODS OF PREVENTING OR TREATING RECURRENCE OF MYOCARDIAL INFARCTION | Decode Genetics EHF. (IS) | 2006-06-21 | — | — | EP | disclosed |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | DECODE GENETICS, INC. (IE) | 2006-01-26 | — | — | US | disclosed |
| US-20050272051-A1 | Methods of preventing or treating recurrence of myocardial infarction | DECODE GENETICS EHF. (IS) | 2005-12-08 | — | — | US | disclosed |
| WO-2005075022-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005027886-A2 | METHODS OF PREVENTING OR TREATING RECURRENCE OF MYOCARDIAL INFARCTION | DECODE GENETICS EHF. (IS) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | TNNI3, TSG101, ALDH1B1 | LTA4H 91/4885ACHE 4204/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | LTA4H 4/4885ACHE 3057/4885 |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | PLAAT3, PLAAT2, PLA2G7 | LTA4H 64/4885ACHE 3885/4885 |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | PLAAT3, PLAAT2, PLA2G7 | LTA4H 56/4885ACHE 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.